Dr. Black Discusses the Impact of Durvalumab in Bladder Cancer

Peter Black, MD
Published: Friday, Jul 21, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses the impact of durvalumab (Imfinzi) in bladder cancer.

Durvalumab is approved for use in patients with locally advanced or metastatic bladder cancer who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

In addition to treating patients, durvalumab has brought a lot of industry and research interest to bladder cancer, says Black.


Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses the impact of durvalumab (Imfinzi) in bladder cancer.

Durvalumab is approved for use in patients with locally advanced or metastatic bladder cancer who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

In addition to treating patients, durvalumab has brought a lot of industry and research interest to bladder cancer, says Black.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x